By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) Reports Full Year 2016 Financial Results And Provides Business Update 3/23/2017 6:40:01 AM
AVEO Oncology (AVEO) Announces First Patient Dosed In Phase 1/2 Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In Advanced RCC 3/22/2017 6:33:06 AM
AVEO Oncology (AVEO) Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review 2/23/2017 6:23:31 AM
AVEO Oncology (AVEO) Announces Clinical And Regulatory Updates For Tivozanib 2/10/2017 6:46:58 AM
AVEO Oncology (AVEO) Reports Third Quarter 2016 Financial Results And Provides Business Update 11/4/2016 11:03:24 AM
AVEO Oncology (AVEO) To Present At The 15th Annual BIO Investor Forum 10/12/2016 10:17:23 AM
AVEO Oncology (AVEO) Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation 10/3/2016 10:39:25 AM
Struggling AVEO Oncology (AVEO) Quietly Discontinues Phase II Ficlatuzumab Study 9/12/2016 6:05:41 AM
AVEO Oncology (AVEO) To Present At The 18th Annual Rodman & Renshaw Global Investment Conference 9/6/2016 11:30:24 AM
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma 8/15/2016 11:58:09 AM